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Objectives: To analyze the cost of illness in the management of anemia among 
chronic kidney disease (CKD) patients on hemodialysis MethOds: Prospective 
observational study for a period 7 months was conducted after the approval of the 
protocol by the Ethics Committee. The patients on hemodialysis of both sexes aged 
between 18-75 years were enrolled in the management of anemia with erythropoi-
etin (EPO). The data relating to the cost and the number of units for EPO, Iron and 
Vitamin supplements were recorded and computed on weekly basis. Hemoglobin 
levels were recorded every month. The average cost incurred was calculated for 7 
months. Results: The number of subjects included in the study was 62 out of 96 
patients. The total number of EPO administered for 7 months was computed by 
adding all the doses for 7 months. On an average, each subject was administered 
27.44 of EPO doses equivalent to 113001.35 IU. The Iron supplements and vitamins 
constituted 15.54 doses and 32.6 doses respectively. The response of above-men-
tioned treatment reflected in raise in 8.67 g/dl hemoglobin levels per patient per 7 
months. The cost of EPO for doses administered was 111859.92 INR (1864.32 USD), 
Iron supplements 5594.4 INR (93.24 USD), Vitamin supplements 1587.83 INR (26.46 
USD). In addition, the laboratory charges for the measurement of hemoglobin levels 
were 325 INR (5.41 USD) per patient per 7 months. cOnclusiOns: Study reveals 
64.58% of patients were economically sound to undergo the treatment with EPO. 
Eighteen patients were covered by Employees’ State Insurance and 2 patients sup-
ported by their employers on reimbursement basis and the remaining 40 patients 
borne the expenses by themselves. The study revealed that the average cost in the 
management of anemia among chronic kidney disease patients on hemodialysis 
per patient per 7 months was 119367.15 INR (1989.45 USD).
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Objectives: Chronic kidney disease (CKD) represents a major public health concern 
with a great economic burden. The aim of the study is to estimate the mean annual 
social cost of a patient with CKD by stage (IV and V pre-dialyses) and cost component 
in Italy. MethOds: The cross sectional study included all adult outpatients that 
were in charge of the 14 main Hospital Centers in the Tuscany Region during 7 week. 
Direct medical costs have been estimated using tariff for laboratory test, diagnostic 
exams, visits and hospitalization and price for drugs. Non medical costs included 
the cost of diet, patients and caregivers travel expenses, formal and informal care. 
The loss of productivity of patients and caregivers have been estimated as indirect 
costs using the human capital approach. Costs are expressed as mean (± standard 
deviation) in Euro 2012. Results: 279 patients in stage IV and 205 patients in stage 
V have been enrolled. The estimated mean annual social cost of a patient with 
CKD were € 9,185 (± € 6,319) for stage IV and € 10,766 (± € 8,314) for stage V (p< 0,05). 
Direct medical costs were higher in stage V as compared to stage IV (€ 5,049 ± € 
4,017 versus € 3,840 ± € 4,042, p< 0,05). Direct non medical costs and indirect costs 
accounted respectively for 32% and 26% of the total social cost for CKD stage IV and 
for 26% and 27% of the total social cost for CKD stage V. In Italy the overall annual 
social cost of CKD stage IV and V was € 2,158,903,299 representing the 0.14% of the 
GDP. cOnclusiOns: Direct non medical costs and indirect costs represent the main 
component of the social cost of CKD. Patients, their families and the productivity 
system mainly sustain the burden of the disease.
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Objectives: To investigate the employee’s health insurance payment policy 
for stage-5 chronic renal failure patients treated with dialysis as well as stage1-4 
patients, analyze payment levels of the insurance and out-of-pocket medical 
expense. MethOds: This study involved 8809 stage-5 chronic renal failure cases 
treated with dialysis and 14472 stage1-4 cases in 6 provincial capital & vice-provincial 
cities (Shenyang, Nanjing, Qingdao, Zhengzhou, Chengdu, Urumchi).The actual claim 
data of medical expenses and medical care utilization from 2008 to 2010 were col-
lected. Descriptive analysis was applied to the data. The employee’s health insurance 
payment policies of the 6 cities were reviewed. Results: 1) All the cities provided 
both inpatient and outpatient medical expense payment for stage-5 chronic renal 
failure with dialysis, but for stage1-4 only 3 cities provided both inpatient and outpa-
tient payment while the others did not pay for outpatient.2) The actual payment levels 
of inpatient expense for dialysis ranged from 70% to 80%, and those of outpatient 
ranged from 70% to 90% in various cities. The out-of-pocket expense for inpatient 
and outpatient were US$839 and US$829,respectively. 3) In the 3 cities which pro-
vided both inpatient and outpatient payment for stage1-4 chronic renal failure, the 
actual payment levels for inpatient ranged from 64% to 77% and those of outpatient 
ranged from 61% to 75% . The out-of-pocket expense for inpatient and outpatient 
reached US$510 and US$464, respectively. cOnclusiOns: Generally,health insur-
ance for employees eased the economic burden of stage-5 patients with dialysis and 
made out-of-pocket expense acceptable. Provision of outpatient payment for stage1-4 
patients is necessary in lowering the economic burden and meeting the outpatient 
service demand of the patients. Therefore,the employee’s health insurance should 
strengthen medical service monitoring for dialysis,handle the catastrophic medical 
expense risk of stage-5 patients with extremely high medical expenses and provide 
outpatient payment for stage1-4 patients.
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controlling for age and gender effects on costs. Moreover, a propensity score match-
ing analysis was used to test for robustness of the results. Results: OAB patients 
caused additional annual costs of € 772 compared to non-OAB patients. Patients 
treated with Oxybutynin had the lowest additional costs (€ 660) while patients 
treated with Tolterodine yielded the highest additional costs (€ 1,049). In the special 
case of incontinence, patients treated with Solifenacin incurred the lowest addi-
tional costs (€ 1,242) and patients treated with Tolterodine the highest (€ 1,835). 
The lower treatment costs for Solifenacin are mainly driven by lower spending on 
medical aids, especially due to lower pad usage. All results are highly significant (p 
< 0.01) and propensity score matching produced similar findings. cOnclusiOns: 
This study compares the annual cost of six anticholinergics for the treatment of 
OAB and incontinence in patients 40 years of age or older in Germany. OAB patients 
treated with Oxybutynin and incontinent patients treated with Solifenacin have 
shown the lowest additional cost. For both patient groups Tolterodine is associated 
with the highest additional cost of treatment.
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Objectives: To determine the real-world dose equivalency of sevelamer hydro-
chloride/carbonate (SH/C) and lanthanum carbonate (LC) monotherapies, and 
compare the drug costs associated with various dosages of SH/C versus conver-
sion to LC. MethOds: Data were evaluated retrospectively for patients receiving 
hemodialysis in the US, who converted in either direction between SH/C and LC 
monotherapies, yet had similar phosphate (P) levels over the observation period. 
The study comprised a 90-day pre-conversion period followed by a 90-day post-
conversion period. Serum P and daily P binder doses were assessed across six 30-day 
periods. Primary comparisons were based on data from the last month of each 
treatment period to allow for clinical equilibration. Drug cost assessments were 
based on prescription fills and REDBOOK pricing (Sept 2013). Results: A total of 
303 patients met study criteria: 128 converted from SH/C (mean dose ~8200 mg/day) 
to LC (~3400 mg/day) and 175 converted from LC (~3800 mg/day) to SH/C (~8600 mg/
day). In the post-conversion, serum P ranged from 5.99±1.64 mg/dL to 6.43±1.87 mg/
dL in patients converting from SH/C to LC, and from 6.18±1.68 mg/dL to 6.51±1.92 
mg/dL in those converting from LC to SH/C. For combined patient cohorts, the overall 
dose equivalency of SH/C:LC was 2.27. Mean P binder costs were $1080±491/patient/
month with SH/C and $1006±513 with LC. Mean cost differences between pre- and 
post-conversion phases, in either direction, were –$74.20/patient/month (95%CI 
–141.80, –6.63; p< 0.05) in favor of LC. Cost differences between LC and SH/C were 
greatest (–$359; 95%CI –485, –260; p< 0.001) in favor of LC, in patients receiving > 7200 
mg SH/C daily (50.7% of patients). cOnclusiOns: Patients who converted between 
LC and SH/C monotherapies in either direction maintained similar P levels in both 
conversion phases. LC was 2.27 times as potent as SH/C on an mg-to-mg basis and 
was associated with significantly lower P binder costs.
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Objectives: To compare health care costs among patients who continued ther-
apy or switched antimuscarinic agents for overactive bladder (OAB). MethOds: 
Patients initiating antimuscarinic therapy from 1/1/2007-3/31/2012 diagnosed with 
OAB were identified from a large claims database of privately insured patients. 
Patients were required to have no antimuscarinic claims in the 12 months before 
their antimuscarinic initiation (baseline period), continuous coverage for ≥ 12 
months before and after antimuscarinic initiation, and age 18-64 years. Based on 
claims in the 6 months after antimuscarinic initiation, patients who continued 
index antimuscarinic therapy were categorized as persisters (n= 3,197), and patients 
with a claim for a non-index antimuscarinic agent (without a gap > 60 days after 
the end of index antimuscarinic treatment) were categorized as switchers (n= 828). 
The study index date was defined as the date of switching from index antimus-
carinic for switchers and a randomly assigned date (matching the distribution of 
time from initiation to switching) for persisters. All-cause and OAB-related costs 
(i.e., reimbursements to providers for medical and pharmacy claims) in the month 
prior to and 6 months after the index date were compared using generalized lin-
ear models controlling for baseline characteristics and baseline costs. Results: 
Persisters compared with switchers were older and had lower baseline costs. After 
controlling for baseline characteristics and costs, all-cause and OAB-related costs 
in both the month before and 6 months after the index date were significantly 
lower among persisters than switchers (1 month before: all-cause $1,222 vs. $1,759, 
OAB-related $142 vs. $170; 6 months after: all-cause $7,017 vs. $8,806, OAB-related 
$642 vs. $797; all p< 0.0001). cOnclusiOns: All-cause and OAB-related costs in the 
period immediately before and after switching were higher among patients who 
switched antimuscarinic therapies compared with patients who persisted on their 
index antimuscarinic therapy.
PUK14
ManageMenT of aneMia aMong chronic Kidney diSeaSe PaTienTS on 
heModialySiS: a STUdy of coST of illneSS
Mateti U.V.1, Nagappa A.N.1, Attur R.P.2, Bairy M.2, Nagaraju S.P.2, Balkrishnan R.3
1Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal 
University, Manipal, India, 2Department of Nephrology, Kasturba Medical College, Kasturba 
Hospital, Manipal University, Manipal, India, 3University of Michigan, Ann Arbor, MI, USA
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A293
insufficient with monotherapy. We evaluated the cost and resource utilisation, in 
the UK health care system, of three treatment scenarios: tamsulosin (0.4mg) mon-
otherapy; tolterodine (modified release, 4mg) + tamsulosin given concomitantly; 
and fixed-dose combination (FDC) of solifenacin 6mg + oral controlled absorption 
system [OCAS™] formulation of tamsulosin (TOCAS, 0.4mg). MethOds: A Markov 
model, with a monthly cycle length and 1-year time horizon, compared the cost of 
treating 1,000 men with LUTS/BPH who have moderate-to-severe storage symp-
toms and voiding symptoms. All patients were initially treated with tamsulosin 
monotherapy. Patients with inadequately controlled symptoms at week 12, based 
on Total Urgency and Frequency Score (TUFS, the daily sum of all recorded Patient 
Perception of Intensity of Urgency Scale [PPIUS] scores from micturition diaries), 
were considered for FDC solifenacin 6mg + TOCAS or tolterodine + tamsulosin. 
Patients adequately controlled at week 12 continued tamsulosin monotherapy. 
Thereafter, patients could discontinue therapy each month based on reported 
medication persistence data. Patients who discontinued treatment were eligible 
for surgery or other medical management. Results: Compared with tamsulosin 
monotherapy, total costs per patient, over a 1-year time horizon, were reduced by 
£133.75 for tolterodine + tamsulosin and reduced by £154.85 for FDC solifenacin 
6mg + TOCAS. cOnclusiOns: Our findings suggest FDC solifenacin 6mg + TOCAS 
reduces annual health care costs compared with tamsulosin monotherapy and 
tolterodine + tamsulosin in patients with inadequately controlled storage symp-
toms. Lower total cost for FDC solifenacin 6mg + TOCAS and tolterodine + tamsu-
losin versus tamsulosin monotherapy was largely driven by improved symptom 
control. The relatively lower total cost for FDC solifenacin 6mg + TOCAS versus 
tolterodine + tamsulosin (£21 per patient/year) was principally due to improved 
persistence with FDC solifenacin 6mg + TOCAS.
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Objectives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
insufficient with monotherapy. We evaluated the cost-effectiveness of fixed-dose 
combination (FDC) solifenacin 6mg + oral controlled absorption system (OCAS™) 
formulation of tamsulosin (TOCAS, 0.4mg) versus tolterodine (modified release, 
4mg) + tamsulosin (0.4mg) given concomitantly, from the perspective of the UK 
NHS. MethOds: A Markov model, with a time horizon of 1 year, was developed for 
men with LUTS/BPH who have moderate-to-severe storage symptoms (≥ 8 micturi-
tions/day and ≥ 2 urgency episodes/day [Patient Perception of Intensity of Urgency 
Scale, PPIUS, grade 3 or 4]) and voiding symptoms treated with FDC solifenacin 
6mg + TOCAS or tolterodine + tamsulosin. Treatment success was defined using 
the Total Urgency and Frequency Score (TUFS, the daily sum of all recorded PPIUS 
scores from micturition diaries). The phase 3 NEPTUNE study was used to estimate 
transition probabilities and utilities were derived from analysis of EQ-5D data. Other 
model input parameters included discontinuation rates, derived from a large UK 
database study (THIN). Univariate and probabilistic sensitivity analyses were per-
formed. Results: FDC solifenacin 6mg + TOCAS was associated with lower total 
annual costs (£520 vs £583) and increased quality adjusted life years (QALYs, 0.840 
vs. 0.838), and was therefore dominant compared with tolterodine + tamsulosin. 
Time horizon, discontinuation/withdrawal rates, drug cost and utility values were 
the main drivers of cost-effectiveness. The probability that FDC solifenacin 6mg + 
TOCAS is cost-effective was 100% versus tolterodine + tamsulosin, at a willingness 
to pay threshold of £20,000/QALY gained. cOnclusiOns: FDC solifenacin 6mg + 
TOCAS is dominant compared with tolterodine + tamsulosin for the treatment of 
men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding 
symptoms. To our knowledge, this is the first cost-effectiveness analysis of a FDC 
in this patient population.
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Objectives: The most recent literature has shown extensively that a low protein 
diet in patients with Chronic Kidney Disease (CKD), delays the natural progres-
sion of the end stage renal disease (ESRD) and the necessary treatment of chronic 
dialysis. The aim of this study is to estimate the cost-effectiveness of a low protein 
diet compared with no dietary treatment in patients with CKD stage 4 and 5 after 
2, 3, 5 and 10 years. MethOds: It was developed a Markov model to estimate 
costs and QALYs associated with low protein diet versus no treatment for patients 
with CKD stage 4-5. The transition probability was estimated on data from seven 
studies which determined the efficacy of low protein diets in delaying the need 
to start maintenance dialysis. Utilities and cost were estimated from literature 
review and projected for the lifespan considered in the model. The annual cost 
of dialysis per patient was approximately € 34,072. The costs of a low-protein diet 
was € 1,440 per patient per year in the Lazio Region (conservative assumptions). 
Probabilistic and Deterministic sensitivity analysis were performed. Results: The 
model estimate that low-protein diet should be more effective. Dietary treatment 
improve 0.09 QALYs after two years, 0.16 after three years, 0.36 after five years and 
up to 0.93 incremental QALYs after the first 10 years. After two years the model 
estimate incremental cost in favour of dietary treatment of € 1,325, € 3,023, € 6,906 
and € 13,829 for 2, 3, 5 and 10 years of follow-up respectively. cOnclusiOns: The 
results of these simulations indicate that the treatment of CKD patients with a 
Objectives: To analyze the cost of hemodialysis (HD) and peritoneal dialysis (PD) 
in different regions of Russia. MethOds: Open source information search. Direct 
cost analysis. Results: During the information search current tariffs have been 
found for 25 regions for HD and for 11 regions for PD. Tariff per one HD procedure 
has ranged from $ 96 for the republic Chuvashia to $ 319 for the the Khanty-Mansi 
Autonomous Area, i.e. annual cost of the HD per patient amounted to $ 14976 
and $ 49764, respectively. The cost of a single procedure HD in Moscow was $ 162, 
which corresponds to an annual expenditure of approximately $ 25272 per patient. 
 The average cost of the procedure HD in the Russia amounted to about $ 150 
and the annual cost of HD for one patient - $ 23400. The cost of one exchange 
PD ranged from $ 15 in the Nizhny Novgorod region to $ 84 in the Khanty-Mansi 
Autonomous Area. Thus, the annual costs on the PD upon 4 exchanges per day for 
per patient in these regions were $ 21900 and $ 122640, respectively. The cost of 
one PD exchange in Moscow was $ 26, which corresponds to an annual expendi-
ture of approximately $ 37960 per patient. The average cost of one exchange PD 
in Russia amounted to $ 22, and the average annual cost per patient - $ 32120 
(accepted exchange rate was 1 $ = 33,35 RUB). cOnclusiOns: Thus, during the 
cost analysis it has been revealed that the cost of dialysis among the subjects of 
Russia differs in more than 3 times, despite the fact that the same set of medical 
services is provided in each region.
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Objectives: To understand the trends in rate and cost of hospitalizations due 
to Chronic Kidney Disease (CKD) in the U.S. MethOds: We analyzed the last five 
years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal 
Disease (ESRD). The annual number of hospitalizations for specific diagnosis was 
obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. 
Data was also analyzed for length of stay (LOS), charges and cost of hospitaliza-
tion. Results: During the last five years the number of hospitalizations with 
diagnosis of CKD and ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, 
an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of CKD 
and ESRD respectively. The mean LOS for patients with CKD increased from 4.9 to 
5.5 days between2005-2009. The mean LOS for patients with ESRD has remained 
steady at ~6 days between 2005-2009. The cost of hospitalization with diagnosis 
of CKD has increased 31% between 2005-2009. The cost of hospitalization with 
diagnosis of ESRD has increased 21% between 2005-2009. In 2009, the mean cost of 
hospitalization for patients with CKD and ESRD was $11,209 and $21,358, respec-
tively. cOnclusiOns: Hospitalizations due to CKD and ESRD have significantly 
increased during the last five years. There is a need for prevention, treatment, and 
disease management programs to lower the medical and socioeconomic burden 
of this disease.
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Objectives: Although delayed graft function (DGF) on kidney transplantation 
outcomes have been associated with worse allograft and patient survival, the cost 
impact has not been recently explored using a large retrospective database and 
assessed after transplantation hospitalization. Our objective was to determine the 
financial impact of delayed graft function (DGF) in primary kidney transplant recipi-
ents of deceased (DD) and living donor (LD) recipients in the early post-operative 
and long-term follow-up periods. MethOds: A retrospective analysis of USRDS 
and Medicare claims from 2004-2009. Subjects excluded were multiple transplants, 
donor < 5 yo, and transplantation payments < $15,000. DGF was defined at requiring 
dialysis within the first week post-transplantation. Total direct medical costs were 
assessed for 1, 3, 6, 12, 24, and 36-month time intervals post-transplant. Uni-variate 
analyses of covariates were assessed for association with log-transformed charges. 
Significant variables (p< 0.05) were included in multivariate regression. Base charge 
was calculated using an mean of standard demographic and outcome characteris-
tics. Results: After application of exclusion criteria and data validation, 22,616 DD 
and 7,373 LD recipients were evaluated. In multivariate analysis, DGF was an inde-
pendent predictor of charges at 1, 3, 6, and 12 months of $3,920 (p< 0.0001), $1,962 
(p< 0.0001), $839 (p= 0.006) and $1,026 (p= 0.019), respectively in DD. In LD, DGF was 
an independent predictor of charges at 1, 3, and 6 months of $145 (p= 0.012), $4,558 
(p< 0.0001), and $3,629 (p= 0.001), respectively. cOnclusiOns: DGF is a significant 
independent predictor of greater health resource utilization in renal transplanta-
tion that impacts costs beyond the transplant hospitalization. This impact extends 
longer in DD compared to LD. This information should be considered in addition to 
clinical outcomes expected based on the individual transplant candidate to deter-
mine likelihood of successful patient and allograft outcomes.
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Objectives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
